M&A Deal Summary

Bausch Health Acquires PharmaSwiss SA

On February 2, 2011, Bausch Health acquired life science company PharmaSwiss SA from Enterprise Investors for 350M EUR

Acquisition Highlights
  • This is Bausch Health’s 7th transaction in the Life Science sector.
  • This is Bausch Health’s 10th largest (disclosed) transaction.
  • This is Bausch Health’s 1st transaction in Switzerland.

M&A Deal Summary

Date 2011-02-02
Target PharmaSwiss SA
Sector Life Science
Buyer(s) Bausch Health
Sellers(s) Enterprise Investors
Deal Type Add-on Acquisition
Deal Value 350M EUR

Target

PharmaSwiss SA

Zug, Switzerland
website
The largest third-party pharma sales and marketing outsourcing company in the Central and Eastern European region. In 2008 our fund invested EUR35 million in a capital increase transaction to acquire 13% of PharmaSwiss. EI supports the company's expansion in other CEE markets.

Search 190,634 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bausch Health

Laval, Quebec, Canada

website


Category Company
Sector Life Science
Employees19,900
Revenue 8.1B USD (2022)
DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.


DEAL STATS #
Overall 9 of 35
Sector (Life Science) 7 of 21
Type (Add-on Acquisition) 7 of 25
Country (Switzerland) 1 of 1
Year (2011) 1 of 7
Size (of disclosed) 10 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-10-29 Hamilton Pharmaceutical - Sun Care and Skin Therapy Brands

Australia

Hamilton Pharmaceutical - Sun Care and Skin Therapy Brands comprises brands that include skin care products. The products include face sunscreens and skin therapy moisturizers and other treatment products.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-03 GlaxoSmithKline - Zovirax

United Kingdom

GlaxoSmithKline - Zovirax(R) which features aciclovir as its active ingredient, is an antiviral treatment for cold sores.

Buy $300M

Seller(S) 1

SELLER

Enterprise Investors

Warsaw, Poland

Investor Investor

website


Category Private Equity Firm
Founded 1990
PE ASSETS 2.5B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

Enterprise Investors is a private equity firm focused on investments in Central and Eastern Europe, with a primary interest on opportunities in Poland. Enterprise Investors is a generalist investor and looks to commit €30 to €50 million in medium-sized businesses. Enterprise Investors was formed in 1990 and is headquartered in Warsaw.


DEAL STATS #
Overall 4 of 32
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 14
Country (Switzerland) 1 of 1
Year (2011) 1 of 2
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-12-01 Kruk

Wroclaw, Poland

Kruk is a multi-operator offering a full range of loss prevention and debt collection services. Kruk enforces the claims of both financial institutions and large corporate customers. Kruk was founded in 1998 and is based in Wroclaw, Poland.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-04-07 DGS SA

Wloclawek, Poland

DGS SA largest Polish manufacturer of metal closures for alcoholic beverage bottles and glass jars.

Sell €80M